Episodios

  • Delivering Equitable Cancer Care: What Every Healthcare Professional Should Know

    Delivering Equitable Cancer Care: What Every Healthcare Professional Should Know
    Dec 17 2025

    Raymond Mailhot, MD, MPH, University of Miami, Miami, FL

    Recorded on December 2, 2025


    Raymond Mailhot, MD, MPH
    Department of Radiation Oncology
    University of Miami
    Miami, FL
    Join us with Dr. Raymond Mailhot from the University of Miami as we explore how social determinants of health shape patient experiences, treatment decisions, and outcomes. He discusses the importance of cultural competence in delivering equitable, patient-centered care and shares practical communication strategies to better engage patients and collaborate effectively. This episode offers actionable insights to strengthen relationships and improve overall care quality. Tune in today to gain practical strategies that will enhance your approach to patient-centered care and drive better outcomes!

    Additional Blood Cancer United Resources:

    • Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
    • Blood Cancer United Medical Debt Case Management Program for Patients
    • Blood Cancer United Additional Resources for Patients
    Más Menos
    31 m
  • Hairy Cell Leukemia: Strategies for Improved Patient Outcomes

    Hairy Cell Leukemia: Strategies for Improved Patient Outcomes
    Nov 20 2025

    Paul J. Hampel, MD, Mayo Clinic, Rochester, MN

    Recorded on November 4, 2025


    Paul J. Hampel, MD
    Assistant Professor of Medicine
    Division of Hematology, Department of Medicine
    Mayo Clinic
    Rochester, MN
    In this episode, Dr. Paul Hampel from Mayo Clinic Rochester takes a comprehensive look at hairy cell leukemia (HCL). He reviews the current diagnostic work-up, including immunophenotypic and molecular testing, and highlights key clinical features that distinguish HCL from related disorders. Dr. Hampel also discusses approved frontline therapies and evidence-based approaches for relapsed or refractory disease, with attention to infection risk and supportive care. The conversation explores emerging agents, novel combinations, and clinical trials shaping the next wave of HCL management. Join us for this expert discussion, offering practical insights to enhance care and outcomes for patients with HCL.

    Más Menos
    40 m
  • Managing CML: What HCPs Need to Know

    Managing CML: What HCPs Need to Know
    Nov 6 2025

    Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY

    Recorded on October 23, 2025


    Michael J. Mauro, MD
    Director, Chronic Myeloid Leukemia Program
    Professor of Medicine, Leukemia Service
    Memorial Sloan Kettering Cancer Center
    New York, NY
    Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center on the evolving management of chronic myeloid leukemia (CML) in the era of tyrosine kinase inhibitors (TKIs) and newly approved FDA therapies. Dr. Mauro explores how TKIs have transformed prognosis, key factors guiding initial therapy selection, and best practices for managing treatment-related side effects. He also shares updates on TKI discontinuation criteria, long-term monitoring, and a forward look at ongoing trials and emerging therapeutic advances shaping the future of CML care. Gain actionable insights to enhance patient outcomes today!

    Más Menos
    37 m
  • Understanding MRD: Insights for clinical practice and patient care

    Understanding MRD: Insights for clinical practice and patient care
    Oct 10 2025

    Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA

    Recorded on September 25, 2025


    Rahul Banerjee, MD, FACP
    Assistant Professor
    Fred Hutchinson Cancer Center
    Seattle, WA
    In this episode, Dr. Rahul Banerjee from Fred Hutchinson Cancer Center in Seattle, WA, discusses the evolving role of measurable residual disease (MRD) in hematologic malignancies. He explores what MRD is, how assays are used and interpreted, and its impact across the disease continuum. The conversation also covers MRD’s role in clinical trials, how to effectively explain MRD to patients, practical considerations for testing in community settings, and key education resources for both healthcare professionals and patients. Tune in today to gain practical insights you can apply in your daily practice!

    This episode is supported by Adaptive Biotechnologies Corporation and Allogene Therapeutics.
    Más Menos
    32 m
  • Pediatric Acute Leukemias: Focus on clinical trials for treatment

    Pediatric Acute Leukemias: Focus on clinical trials for treatment
    Sep 19 2025

    Ann Collins, PA, Blood Cancer United, Washington, DC, Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC, Sarah K. Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA

    Recorded on September 9, 2025


    Ann Collins, PA
    Project Leader, Pediatric Acute Leukemia Master Clinical Trial (PedAL)
    Blood Cancer United
    Washington, DC
    Kelly Laschinger, MSN, RN, CPNP, CPHON
    Director, Clinical Trial Support Center
    Blood Cancer United
    Washington, DC
    Sarah K. Tasian, MD
    Blood Cancer United PedAL Master Clinical Trial Lead
    Associate Professor of Pediatrics, University of Pennsylvania School of Medicine
    Chief of Hematologic Malignancies Program, Children’s Hospital of Philadelphia
    Philadelphia, PA
    Join us for our first episode as Blood Cancer United! In this episode, Dr. Sarah Tasian, from Children’s Hospital of Philadelphia, and Ann Collins and Kelly Laschinger, from Blood Cancer United, join us for an in-depth discussion on pediatric acute leukemias. The conversation delves into the latest therapies, treatment challenges, and the complex realities of long-term survivorship. We also explore the groundbreaking Blood Cancer United Pediatric Acute Leukemia Master Clinical Trial (PedAL), its bold vision, global collaboration, and unified approach to data collection. Valuable clinical trial resources and strategies to support patients, families, and healthcare professionals are also shared. Tune in today!

    Más Menos
    38 m
  • Charting the Course of ALL: From Diagnosis to Advances

    Charting the Course of ALL: From Diagnosis to Advances
    Jul 9 2025

    Catherine Lai, MD, MPH, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, PA

    Recorded on June 27, 2025


    Catherine Lai, MD, MPH
    Associate Professor
    Physician Leader, Leukemia Clinical Research Unit
    University of Pennsylvania Perelman Center for Advanced Medicine
    Philadelphia, PA
    In this episode, Dr. Catherine Lai, from the University of Pennsylvania’s Perelman Center for Advanced Medicine, joins us to discuss the current landscape of adult acute lymphoblastic leukemia (ALL) treatment. She highlights recent advances in frontline and relapsed therapies, the critical role of measurable residual disease (MRD), and the use of immunotherapy and targeted treatments. Dr. Lai further explores transplant considerations, management of side effects, and tailored approaches for B-cell and T-cell ALL. She also emphasizes patient-centered care, including strategies for end-of-life discussions and shared decision-making. Tune in today for expert insights and practical takeaways on the evolving future of ALL care!

    Más Menos
    37 m
  • Strategies and Advances in AML

    Strategies and Advances in AML
    Jun 12 2025

    Uma Borate, MBBS, MS, The Ohio State University, Columbus, OH

    Recorded on May 27, 2025


    Uma Borate, MBBS, MS
    Associate Professor, Division of Hematology
    Acute Leukemia Clinical Research Disease Group Leader
    The Ohio State University
    Columbus, OH
    What’s changing in acute myeloid leukemia (AML)? Join Dr. Uma Borate from The Ohio State University in Columbus, Ohio, as she dives into emerging breakthroughs in AML biology, including molecular drivers, menin inhibitors, and the challenges of developing bispecifics and CAR T-cell therapies. She also shares updates from the LLS Beat AML® Master Clinical Trial and ongoing clinical trials, and reflects on the evolving treatment landscape across age groups. Don’t miss this dynamic conversation packed with expertise and hope for the future of AML!

    Más Menos
    38 m
  • Advancing Care in Myeloproliferative Neoplasms (MPNs)

    Advancing Care in Myeloproliferative Neoplasms (MPNs)
    May 29 2025

    Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH

    Recorded on May 13, 2025


    Aaron Gerds, MD, MS
    Associate Professor of Medicine
    Cleveland Clinic Lerner College of Medicine
    Case Western Reserve University School of Medicine
    Medical Director
    Case Comprehensive Cancer Center Clinical Research Office
    Cleveland, OH
    In this episode, Dr. Aaron Gerds from the Cleveland Clinic explores the intricacies of Myeloproliferative Neoplasms (MPNs), from diagnosis and monitoring to treatment goals and the latest therapeutic advances. Dr. Gerds discusses emerging therapies, the significance of clinical trials, strategies for managing side effects and long-term effects, and valuable resources for healthcare professionals, patients, and families. Tune in today for expert insights on MPNs!

    This episode is supported by GSK plc and Karyopharm Therapeutics.
    Más Menos
    33 m